Yüklüyor......
Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment
Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia (CML). Imatinib at a dose of 400 mg/day is considered the standard treatment for all newly diagnosed chronic phase CML. Follow-up on the pivotal International Randomized Study of I...
Kaydedildi:
| Yayımlandı: | Hematol Oncol Clin North Am |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428141/ https://ncbi.nlm.nih.gov/pubmed/22054730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2011.09.004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|